振東製藥(300158.SZ)擬解除並終止資產置換事宜
格隆匯6月1日丨振東製藥(300158.SZ)公佈,公司於2021年5月31日召開了第四屆董事會第十八次會議,審議通過了《關於終止資產置換暨關聯交易的議案》,由於安特製藥2018-2020年分別虧損8151萬元、4919萬元和3516萬元,公司擬剝離長期虧損資產安特製藥。
安特製藥旗下治療脱髮的達霏欣米諾地爾搽劑前幾年銷售差,不是公司主要經營品種。今年,男性醫美和脱髮經濟等醫美題材受到廣泛關注,達霏欣米諾地爾的銷售增速很快,2021年第一季度的銷售額達5000萬元,第二季度預估也會有很大的增長。同時,公司代理銷售的防脱髮的咖啡因洗髮水,與生髮的達霏欣匹配組合,可以打造成一個相輔相成的醫美產品系列。
公司於2021年5月31日召開了第四屆董事會第十八次會議以6票通過,0票反對,0票棄權審議通過了《關於終止資產置換暨關聯交易的議案》,雙方一致同意,自本協議生效之日起,《資產置換協議》即予以解除並終止資產置換事宜,雙方就《資產置換協議》的解除不存在任何異議。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.